Akeso Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Akeso de 12.2% y 18.6% por año respectivamente. Se prevé que el BPA crezca en un 1.3% al año. Se espera que la rentabilidad financiera sea de 21.5% en 3 años.

Información clave

10.8%

Tasa de crecimiento de los beneficios

0.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	35.4%
Tasa de crecimiento de los ingresos	18.4%
Rentabilidad financiera futura	21.5%
Cobertura de analistas	Good
Última actualización	24 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Aug 31

Recent updates

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Apr 24

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Mar 25

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Dec 28

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Nov 16

Is Akeso (HKG:9926) Using Too Much Debt?

Oct 02

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Aug 31

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Mar 21

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Mar 02

Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Aug 28

Is Akeso (HKG:9926) Using Too Much Debt?

Apr 10

Akeso (HKG:9926) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Dec 28

Is Akeso (HKG:9926) Using Too Much Debt?

Sep 05

Previsiones de crecimiento de beneficios e ingresos

SEHK:9926 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	6,090	1,338	1,323	1,834	15
12/31/2025	4,245	247	122	292	18
12/31/2024	2,679	-406	-596	-363	17
12/31/2023	4,526	2,028	2,468	2,468	N/A
9/30/2023	4,439	2,008	1,899	2,340	N/A
6/30/2023	4,351	1,987	1,330	2,212	N/A
3/31/2023	2,595	409	-356	486	N/A
12/31/2022	838	-1,168	-2,043	-1,240	N/A
9/30/2022	549	-1,224	-1,997	-1,238	N/A
6/30/2022	260	-1,280	-1,952	-1,235	N/A
3/31/2022	243	-1,178	-1,835	-1,118	N/A
12/31/2021	226	-1,075	-1,717	-1,001	N/A
9/30/2021	177	-1,002	-1,525	-882	N/A
6/30/2021	129	-929	-1,333	-762	N/A
3/31/2021	64	-983	-1,200	-690	N/A
12/31/2020	N/A	-1,036	-1,066	-618	N/A
9/30/2020	35	-870	-814	-443	N/A
6/30/2020	71	-703	-562	-267	N/A
3/31/2020	71	-492	-459	-243	N/A
12/31/2019	71	-282	-356	-220	N/A
12/31/2018	3	-142	-198	-123	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (12.2% al año) de 9926 es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: Se prevé que los beneficios (10.8% al año) de 9926 crezcan menos que el mercado Hong Kong (11.5% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 9926 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (18.6% al año) de 9926 crezcan más rápidamente que los del mercado Hong Kong (7.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 18.6% al año) de 9926 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 9926 sea alta dentro de 3 años (21.5%)

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Akeso Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Forecast to breakeven in 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Is Akeso (HKG:9926) Using Too Much Debt?

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2023

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Akeso, Inc. Announces China NMPA Approved Anniko (Penpulimab) for First-Line Treatment of Locally Advanced or Metastatic Squamous NSCLC

Now 24% undervalued

Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) Mechanism Shows Promising Antitumor Efficacy and Favorable Safety Profile

Forecast to breakeven in 2023

Less than half of directors are independent

Akeso, Inc. Announces Ivonescimab Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China

Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC

Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022

No longer forecast to breakeven

Akeso's Ivonescimab (PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC

Akeso, Inc. Develops Combination Therapies Based on Its PD-1 BsAbs, Ivonescimab (PD-1/VEGF) in Combination with Drebuxelimab (CD73) Approved for a Clinical Trial on Treating Advanced Solid Tumors

Akeso, Inc. Announces Commencement of Phase Ib/II clinical trial

Forecast to breakeven in 2024

Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Akeso, Inc. Publishes First Approval of Cadonilimab in Drugs, A Peer-Reviewed Medical Journal

Akeso, Inc. to Report First Half, 2022 Results on Aug 23, 2022

Akeso's Cadonilimab (Pd-1/Ctla-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China

Akeso, Inc. Reports Results of Phase IB/II Clinical Trial of Ivonescimab Monotherapy for Advanced Non-Small Cell Lung Cancer Published At the 2022 ASCO Annual Meeting

Akeso, Inc. Announces Oral Presentation Featuring Promising Clinical Data of Cadonilimab (PD-1 CTLA-4 BsABs, AK104) for the First-Line Treatment of R/M Cervical Cancer at ASCO 2022

Akeso, Inc., Annual General Meeting, Jun 28, 2022